NEJM Study Reveals Pfizer’s Antiviral Drug Paxlovid Does ‘Little or Nothing’ Against COVID-19 (VIDEO)
A new study published in the New England Journal of Medicine (NEJM) raises serious questions about the efficacy of Pfizer’s antiviral drug Paxlovid, which was previously authorized for emergency use to treat mild to moderate COVID-19 cases.
Paxlovid received emergency use authorization in December 2021 as the first at-home treatment for COVID-19 in the United States. It was touted as a cost-effective and efficient method to combat early COVID-19 infections.
Pfizer reported that Paxlovid significantly reduced the risk of COVID-19-related hospitalization or death by 88% in their press release.
The Gateway Pundit has been covering the inefficacy and adverse reactions associated with Pfizer’s antiviral drug.
Scientific documentation about post-Paxlovid relapse has been available since the fall of 2022.
